Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small-cell Lung Cancer: early-phase trial registry
38 of 80 indexed Small-cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #173 of 28,707 conditions by registered trial count.
80 US clinical trials · 38 currently recruiting · #173 of 28,707 conditions by registered trial count
Small-cell Lung Cancer: 80 US clinical trials tracked, 38 recruiting.
Small-cell Lung Cancer is the subject of 80 registered US clinical trials on ClinicalTrials.gov, 38 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 5 of these trials.
Enrollment posture brief
Registry condition small-cell-lung-cancer
OPEN 38 | RECR 48% | LATE 11 | EARLY 54 | RANK #173 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Metastatic Lung Non-Small Cell Carcinoma (48% recruiting · 40 trials)
Small-cell Lung Cancer lists 38 open slots (48% of 80 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small-cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small-cell Lung Cancer is recruiting above its size-band peers.
38 of 80 indexed trials (47.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Small-cell Lung Cancer trials is spread across many organizations.
Amgen accounts for 5 of 80 trials (6.3%). 67 distinct sponsors appear on at least one study for this condition label.
-
Typical Small-cell Lung Cancer enrolment sits around 80 participants.
Median target enrolment is 80 among the 80 trials that report a genuine target (sentinel values excluded). 42 of those (52.5%) plan for fewer than 100 participants.
-
Small-cell Lung Cancer research is mostly interventional.
71 interventional and 9 observational studies make up this index (88.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
80 total, page 2 of 2
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center
NCT04165330
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC
Advenchen Pharmaceuticals
NCT05363280
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
NCT05616624
Study of AZD2811 + Durvalumab in ES-SCLC
AstraZeneca
NCT04745689
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03923270
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
Yale University
NCT03670056
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
NCT04010357
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
Ipsen
NCT03088813
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Hoffmann-La Roche
NCT04256421
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
NCT02349412
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NCT04332653
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
NCT00531284
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Eli Lilly and Company
NCT02735980
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics
NCT03041311
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
NCT04247126
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
AbbVie (prior sponsor, Abbott)
NCT00445198
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
Celgene Corporation
NCT00319969
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Mundipharma Research Limited
NCT03345485
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
H. Lee Moffitt Cancer Center and Research Institute
NCT00617409
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Impact Therapeutics
NCT04434482
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Eli Lilly and Company
NCT03898791
Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer
University of Southern California
NCT02273336
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
SCRI Development Innovations
NCT00294190
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
Zhonglin Hao
NCT03958045
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
University of Alabama at Birmingham
NCT00856830
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Mersana Therapeutics
NCT00455052
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01797159
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC
University of Michigan Rogel Cancer Center
NCT00156286
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting
Wake Forest University Health Sciences
NCT03741829
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 23 |
| Phase 3 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Small-cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small-cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small-cell Lung Cancer page
80 registered trials, 38 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 38 Small-cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Small-cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small-cell Lung Cancer condition card totals 80 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.